Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2007, Vol. 12 ›› Issue (1): 28-31.

Previous Articles     Next Articles

Effects of glucagon-like peptide-1 prodrug on glycemia control in non-diabetic mice

MA Xue1, HUI Hong-xiang2,3, LIU Zhen-guo1, WU Yu-mei1, MENG Jia1, LUO Xiao-xing1   

  1. 1Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi' an 710032, Shanxi, China, Los Angeles, CA90048, USA,
    2Department of Medicine, University of California; 3Division of Endocrinology &Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
  • Received:2006-09-27 Revised:2006-11-03 Online:2007-01-26 Published:2020-10-26

Abstract: AIM: To study the effects of proglucagonlike peptide-1, a long-acting prodrug glucagon-like peptide-1, on regulations of blood glucose levels and insulin secretion in non-diabetic mice. METHODS: Pro-GLP-1 was administered via scroute.Blood glucose levels were measured using a blood glucose meter.Plasma insulin concentrations were determined by ELISA. RESULTS: In C57BL 6 mice, native GLP-1 and Pro-GLP-1 decreased blood glucose, but Pro-GLP-1 had a more evident action.A single injection of Pro-GLP-1 dose-dependently reduced higher glucose following glucose load at least 3 h,and it had no effect on normal blood glucose.Moreover, it dose-dependently stimulated insulin secretion and significantly improved glucose tolerance after glucose challenge. CONCLUSION: These results demonstrate that Pro-GLP-1 facilitates a dose-dependently significant and prolonged glucose-lowering effect.

Key words: diabetes, glucagon-like peptide-1, prodrug, blood glucose, insulin

CLC Number: